<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915005</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0133</org_study_id>
    <secondary_id>NCI-2011-01094</secondary_id>
    <secondary_id>2P01CA021239-29A1</secondary_id>
    <nct_id>NCT00915005</nct_id>
  </id_info>
  <brief_title>Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence</brief_title>
  <official_title>A Bayesian Randomized Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if, compared with regular x-ray
      radiation, proton radiation reduces the risk of developing, treatment-related pneumonitis
      (TRP) or tumor recurrence (the tumor coming back in the irradiated area after treatment) in
      patients with lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are 2 types of radiation treatment being used in this study. One type of treatment is
      proton therapy. Proton therapy is a type of radiation therapy that uses a beam of proton
      particles (similar to getting an x-ray) to send radiation inside the body to the tumor. The
      other type of treatment is Image-Guided Adaptive Photon Therapy (IGAPT). IGAPT is a therapy
      that uses images to help guide the delivery of photon therapy to the tumor. Both of these
      types of radiation treatment are believed to help doctors to give a full dose of radiation
      treatment to the tumor while not damaging as much of the healthy tissue around it.

      Study Groups If you are found to be eligible to take part in this study, you will go through
      the standard radiation treatment planning procedure, called the &quot;marking session.&quot; After the
      marking session, a standard photon therapy plan (called Intensity Modulated Radiation
      Therapy, or IMRT) and a proton plan will be developed. If the radiation oncologist thinks
      that both the photon and proton plans are acceptable, you will then be randomly assigned to 1
      of 2 groups. Participants in Group 1 will receive photon therapy. Participants in Group 2
      will receive proton therapy.

      The first 20 participants will have an equal chance to be assigned to either group. After at
      least 20 participants have been enrolled and there has been at least 1 occurrence of
      pneumonitis and/or tumor recurrence in each treatment Group, the risk of pneumonitis and/or
      tumor recurrence in all previous participants will be evaluated for each treatment Group, and
      that information will be used to calculate the chances of being assigned to either Group 1 or
      Group 2. This calculation will be updated after each occurrence of pneumonitis and/or tumor
      recurrence and after each participant returns for a follow-up visit. Once these calculations
      are begun, everyone who joins the study from that point on will be more likely to be assigned
      to the treatment Group that appears to be better in terms of pneumonitis and/or tumor
      recurrence.

      If the tumor is too large and the standard radiation treatment plan created during the
      marking session is found not to be acceptable, and the radiation oncologist thinks radiation
      treatment it is necessary, you will still remain on study and be assigned to a third group.
      If you are assigned to Group 3, you will receive proton or photon treatment at a lower dose
      level and/or reduced length of radiation.

      If you are assigned to Group 2 and your insurance provider denies reimbursement, you may
      chose not to receive proton therapy and receive photon therapy instead. If you chose to
      receive photon therapy, you will be in Group 4.

      Radiation Therapy Administration Both radiation therapy treatments (photon and proton) are
      given through a radiation machine called an accelerator. The radiation therapy administration
      process is very similar to the way that a CT scan is performed. You will lay on a table and
      the treatment machine rotates around you without touching your body. Each daily treatment
      should take about 20-30 minutes to complete. Most of this time is used to position you
      correctly before the machine is turned on. The actual time used to give the radiation should
      take about 3-5 minutes each day.

      While you are on this study and if you are in Groups 1 or 2, you will receive a total of 37
      radiation treatments. Radiation is given 5 days a week for about 7 1/2 weeks.

      If you are in Group 1, you will receive photon radiation treatment in the main hospital.

      If you are in Group 2, you will receive proton therapy in the proton treatment center (PTC).

      If you are in Group 3, you will receive either photon or proton therapy, whichever your
      doctor decides is better for you, for 6-7 1/2 weeks. If your doctor decides that photon
      therapy is better you will receive your treatment in the main hospital. If your doctor
      decides that proton therapy is better you will receive your treatment in the Proton Therapy
      Center.

      If you are in Group 4, you will receive Photon radiation treatment in the main hospital.

      Chemotherapy You will receive carboplatin and paclitaxel chemotherapy 1 time a week over 7
      weeks. Each treatment will last 3-4 hours. Paclitaxel will be given by vein over 1 hour and
      carboplatin will be given by vein over 30 minutes. You will receive this chemotherapy
      combination with radiation therapy, as part of your treatment on this study.

      Your chemotherapy may also be decided by your treating medical oncologist as long as the
      therapy is allowed by the study.

      Study Visits During Chemoradiation

      At least 1 time each week for all study participants, you will have study tests performed.
      During this weekly study visit, the following tests and procedures will be performed:

      You will have a physical exam. You will be asked about any side effects you may have
      experienced. Blood (about 2 teaspoons) will be drawn for routine tests.

      If the study doctor thinks it is needed, you will have a PET/CT scan performed to check the
      status of the disease during Week 4 or 5 of treatment.

      Length of Study You will remain on study as long you are benefiting. You will be taken off
      study early if the disease gets worse, you experience intolerable side effects, or your
      doctor thinks that it is no longer in your best interest to receive the study treatment.

      Follow-Up Visits After you have completed chemoradiation, the study staff or study nurse will
      contact you 1 time each month to ask you about any symptoms you may have until 6 months after
      chemoradiation. Each phone call should last about 10 minutes.

      You will have your first follow-up visit 4-8 weeks after you have completed chemoradiation.
      You will have additional follow-up visits every 3-4 months for 3 years, every 6 months for
      the next 2 years, and then 1 time every year after that.

      At the first and second follow-up visit the following tests and procedures will be performed:

      You will have positron emission tomography (PET)/computed tomography (CT) scans and single
      proton emission tomography (SPECT) scans to check the status of your lungs and heart if the
      radiation or medical oncologist thinks it is necessary.

      Blood (about 1 teaspoon) will be drawn for routine tests.

      If the radiation oncologist or medical oncologist thinks it is needed, at the follow-up
      visits, you will have breathing function tests performed to check your lung function for up
      to 1 year after the study treatment is complete. For this test, the radiation oncologist,
      medical oncologist or study nurse will have you breathe into a special machine. The radiation
      oncologist or medical oncologist will decide how many tests are to be performed each time.

      PET/CT and SPECT scans will be performed again at any time the radiation oncologist or
      medical oncologist thinks they are needed.

      Other tests may be performed if the study doctor (radiation oncologist, medical oncologist,
      surgeon or pulmonologist) thinks they are needed.

      This is an investigational study. Both proton radiotherapy and IGAPT are FDA approved for the
      treatment of lung cancer.

      Up to 250 patients will take part in this multi-center research study. Up to 205 will be
      enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2009</start_date>
  <completion_date type="Actual">February 24, 2020</completion_date>
  <primary_completion_date type="Actual">February 24, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Incidence and Time to Development of Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) Grade &gt; 3 Treatment-related Pneumonitis (TRP)</measure>
    <time_frame>From date of protocol registration until the date of first documented development of CTCAE v3.0 grade &gt; 3 TRP or local failure, whichever occurs first, in both treatment groups, assessed up to 6 years.</time_frame>
    <description>The Primary Objective is assess and compare the incidence and time to development of CTCAE v3.0 grade &gt; 3 TRP, among IMRT-Group 1 or PSPT-Group 2 using Bayesian randomization. TRP will be diagnosed clinically by the treating investigator. Any questions regarding the diagnosis or grade of TRP will be resolved by the Protocol PI or by his/her designee(s). The outcomes review committee will meet to discuss each and every patient reported to have developed symptomatic TRP. The final grading of TRP will be decided by the outcomes review committee. Diagnosis of TRP included receipt of radiation that included a certain volume of normal lung, radiographic changes that suggested inflammation consistent with the radiation dose distribution within 12 months after starting chemoradiation, and symptoms attributable to TRP. Final TRP outcomes also were reviewed and approved by independent external experts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Incidence and Time to Development of Local Failure (LF)</measure>
    <time_frame>From date of protocol registration until the date of first documented development of CTCAE v3.0 grade &gt; 3 TRP or local failure, whichever occurs first, in both treatment groups, assessed up to 6 years.</time_frame>
    <description>The Primary Objective is assess and compare the incidence and time to development of local failure, among IMRT-Group 1 or PSPT-Group 2 using Bayesian randomization. Local failure was defined as treatment failure within the planning target volume plus a # 1-cm margin. Images used to report Local failure were registered with radiation dose distribution to accurately assess the location of the failure. Biopsy to confirm Local failure was strongly recommended (Data Supplement). An internal outcomes review committee reviewed each event to ensure objectivity and consistency in reporting Local failure. Final RP outcomes also were reviewed and approved by independent external experts.
Tumor recurrence after achieving complete response,
Residual tumor enlargement of 20% or more on CT according to RECIST criteria,
Recurrence of PET FDG Avidity after achieving complete metabolic response,
Increase in FDG avidity in residual tumor,
Pathologically proven recurrence</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">275</enrollment>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1: Photon Therapy - 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.
Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.
Carboplatin AUC 2 by vein 1 time each week for 7 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2: Proton Therapy - 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.
Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.
Carboplatin AUC 2 by vein 1 time each week for 7 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3: Receives either photon or proton therapy, whichever participant's doctor decides is better, for for 6-7 1/2 weeks.
Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.
Carboplatin AUC 2 by vein 1 time each week for 7 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Photon Therapy - Highest practical dose (74 CGE, 66 CGE) radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.
Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.
Carboplatin AUC 2 by vein 1 time each week for 7 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Photon Therapy</intervention_name>
    <description>Group 1: 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Therapy</intervention_name>
    <description>Group 2: 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.
Group 3: 66 Gy with conventional fractionation given 5 days a week for about 6-7 1/2 weeks.
Each daily treatment should take about 20-30 minutes to complete.</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>50 mg/m2 by vein 1 time each week for 7 weeks.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 2 by vein 1 time each week for 7 weeks.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically proven, unresected, locoregionally advanced NSCLC without evidence of
             hematogenous metastases (stage II-IIIB disease according to the 7th edition of the
             AJCC Staging Manual) with exception as defined by inclusion #2).

          2. Patients with solitary brain metastasis without sign of progression in the brain at
             the time of registration will be eligible for this trial if there is clinical
             indication for concurrent chemoradiation to the primary disease in the lung.

          3. Suitability for concurrent chemoradiation therapy per treating radiation oncologists
             or treating medical oncologist's: A) Karnofsky performance score of &gt;/= 70, or ECOG
             0-1 B) Unintentional weight loss &lt;/= 10% during the 3 months before study entry.

          4. Receipt of induction chemotherapy followed by referral for concurrent chemoradiation
             is allowed for this protocol.

          5. Measurable disease on chest x-ray, contrast-enhanced CT, or PET scan.

          6. Locoregional recurrence after surgical resection, if suitable for definitive
             concurrent chemoradiation is allowed for this protocol.

          7. Forced expiratory volume in the first second (FEV1) &gt;/= 1 liters.

          8. Fluorodeoxyglucose (FDG) -PET scan within 3 months before registration. The
             pretreatment (diagnostic) PET/CT should, whenever possible, be performed together with
             the 4-D CT simulation. PET images acquired either at the time of simulation or
             acquired separately should be registered with the planning CT to assist in tumor
             delineation.

          9. Standard pretreatment evaluations (as decided by treating radiation oncologist,
             medical oncologist, surgeons or pulmonologist), to include MRI or CT scan of the
             brain, contrast CT scan of the thorax and upper abdomen, Whole-body PET/CT, pulmonary
             function tests, lung and cardiac single proton emission computed tomography (SPECT),
             liver function tests (LFT), blood chemistry, renal function tests, and complete blood
             count.

         10. Age &gt;/= 18 years but &lt;/= 85 years.

         11. A signed specific informed consent form before study entry.

        Exclusion Criteria:

          1. Small cell histology.

          2. Prior thoracic radiotherapy to regions that would result in overlap of radiation
             therapy fields.

          3. Pregnancy (female patients of childbearing potential must practice appropriate
             contraception).

          4. Enrollment in a clinical trial that specifically excludes IGAPT treatment.

          5. Body weight exceeds the weight limit of the treatment couch.

          6. Oxygen dependent due to preexistent lung disease (COPD, emphysema, lung fibrosis).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhongxing Liao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 4, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <results_first_submitted>May 7, 2020</results_first_submitted>
  <results_first_submitted_qc>May 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 26, 2020</results_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally-advanced non-small-cell lung carcinoma</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Image-Guided Adaptive Conformal Photon</keyword>
  <keyword>Proton Therapy</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Treatment Related Pneumonitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 19, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT00915005/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 19, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT00915005/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 149 lung non-small cell lung cancer (NSCLC) patients with stage II to IV or recurrent tumor were consented, randomized, and treated under 2008-0133 protocol from June 2009 to March 2014. Intensity-modulated (photon) radiotherapy (IMRT) in 92; passive scattering proton therapy (PSPT) in 57.</recruitment_details>
      <pre_assignment_details>A total of 275 NSCLC patients were consented. 2 patients were consented twice and 1 person denied by Massachusetts General Hospital.47 patients were excluded before the planning process began. 44 patients did not allow random assignment. 32 patients were not treated according to protocol allocation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intensity-modulated (Photon) Radiotherapy (IMRT)</title>
          <description>All patients on this trial will receive concurrent weekly carboplatin and paclitaxel chemotherapy with radiation therapy 74 or 66 Gy(RBE).</description>
        </group>
        <group group_id="P2">
          <title>Passive Scattering Proton Therapy (PSPT)</title>
          <description>All patients on this trial will receive concurrent weekly carboplatin and paclitaxel chemotherapy with radiation therapy 74 or 66 Gy(RBE).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient preferred protons therapy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insurance denial</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There were 149 out of 181 participants randomized, treated and evaluable for data analysis. 32 paticipants off-study (IMRT Arm in 13 and PSPT Arm in 19). Patient- and tumor-related characteristics did not differ between IMRT and PSPT groups.</population>
      <group_list>
        <group group_id="B1">
          <title>Intensity-modulated (Photon) Radiotherapy (IMRT)</title>
          <description>All patients on this trial will receive concurrent weekly carboplatin and paclitaxel chemotherapy with radiation therapy 74 or 66 Gy(RBE).</description>
        </group>
        <group group_id="B2">
          <title>Passive Scattering Proton Therapy (PSPT)</title>
          <description>All patients on this trial will receive concurrent weekly carboplatin and paclitaxel chemotherapy with radiation therapy 74 or 66 Gy(RBE).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="92"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="149"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="33" upper_limit="85"/>
                    <measurement group_id="B2" value="67" lower_limit="39" upper_limit="78"/>
                    <measurement group_id="B3" value="66.5" lower_limit="36" upper_limit="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky performance score (KPS)</title>
          <description>The KPS ranking runs from 100 to 0, where 100: &quot;perfect&quot; Normal health, 90: able to carry on normal activity; minor signs or symptoms of disease. 80: normal activity with effort; some signs or symptoms of disease. The KPS was to allow physicians to evaluate a patient's survival. The higher KPS scores, the better treatment outcome.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>KPS≤ 80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KPS≥ 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Induction chemotherapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor histology</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Squamous cell carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NSCLC unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical disease stage (American Joint Committee on Cancer [AJCC] 7th Ed)</title>
          <description>American Joint Committee on Cancer [AJCC] 7th Ed:
Stage IIA: T1-2aN1M0; T2bN0M0 Stage IIB: T2b N1 M0 or T3N0M0 Stage IIIA: T1-2bN2M0 or T3N1-2M0 or T4N0-1M0 Stage IIIB: T1-3N3M0 or T4N2-3M0 Stage IV: M1 The earlier TNM staging, the better treatment outcome</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>AJCC IIA/B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AJCC IIIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AJCC IIIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AJCC IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACC Recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Incidence and Time to Development of Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) Grade &gt; 3 Treatment-related Pneumonitis (TRP)</title>
        <description>The Primary Objective is assess and compare the incidence and time to development of CTCAE v3.0 grade &gt; 3 TRP, among IMRT-Group 1 or PSPT-Group 2 using Bayesian randomization. TRP will be diagnosed clinically by the treating investigator. Any questions regarding the diagnosis or grade of TRP will be resolved by the Protocol PI or by his/her designee(s). The outcomes review committee will meet to discuss each and every patient reported to have developed symptomatic TRP. The final grading of TRP will be decided by the outcomes review committee. Diagnosis of TRP included receipt of radiation that included a certain volume of normal lung, radiographic changes that suggested inflammation consistent with the radiation dose distribution within 12 months after starting chemoradiation, and symptoms attributable to TRP. Final TRP outcomes also were reviewed and approved by independent external experts.</description>
        <time_frame>From date of protocol registration until the date of first documented development of CTCAE v3.0 grade &gt; 3 TRP or local failure, whichever occurs first, in both treatment groups, assessed up to 6 years.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensity-modulated (Photon) Radiotherapy (IMRT)</title>
            <description>All patients on this trial will receive concurrent weekly carboplatin and paclitaxel chemotherapy with radiation therapy 74 or 66 Gy(RBE).</description>
          </group>
          <group group_id="O2">
            <title>Passive Scattering Proton Therapy (PSPT)</title>
            <description>All patients on this trial will receive concurrent weekly carboplatin and paclitaxel chemotherapy with radiation therapy 74 or 66 Gy(RBE).</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence and Time to Development of Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) Grade &gt; 3 Treatment-related Pneumonitis (TRP)</title>
          <description>The Primary Objective is assess and compare the incidence and time to development of CTCAE v3.0 grade &gt; 3 TRP, among IMRT-Group 1 or PSPT-Group 2 using Bayesian randomization. TRP will be diagnosed clinically by the treating investigator. Any questions regarding the diagnosis or grade of TRP will be resolved by the Protocol PI or by his/her designee(s). The outcomes review committee will meet to discuss each and every patient reported to have developed symptomatic TRP. The final grading of TRP will be decided by the outcomes review committee. Diagnosis of TRP included receipt of radiation that included a certain volume of normal lung, radiographic changes that suggested inflammation consistent with the radiation dose distribution within 12 months after starting chemoradiation, and symptoms attributable to TRP. Final TRP outcomes also were reviewed and approved by independent external experts.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Incidence and Time to Development of Local Failure (LF)</title>
        <description>The Primary Objective is assess and compare the incidence and time to development of local failure, among IMRT-Group 1 or PSPT-Group 2 using Bayesian randomization. Local failure was defined as treatment failure within the planning target volume plus a # 1-cm margin. Images used to report Local failure were registered with radiation dose distribution to accurately assess the location of the failure. Biopsy to confirm Local failure was strongly recommended (Data Supplement). An internal outcomes review committee reviewed each event to ensure objectivity and consistency in reporting Local failure. Final RP outcomes also were reviewed and approved by independent external experts.
Tumor recurrence after achieving complete response,
Residual tumor enlargement of 20% or more on CT according to RECIST criteria,
Recurrence of PET FDG Avidity after achieving complete metabolic response,
Increase in FDG avidity in residual tumor,
Pathologically proven recurrence</description>
        <time_frame>From date of protocol registration until the date of first documented development of CTCAE v3.0 grade &gt; 3 TRP or local failure, whichever occurs first, in both treatment groups, assessed up to 6 years.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensity-modulated (Photon) Radiotherapy (IMRT)</title>
            <description>All patients on this trial will receive concurrent weekly carboplatin and paclitaxel chemotherapy with radiation therapy 74 or 66 Gy(RBE).</description>
          </group>
          <group group_id="O2">
            <title>Passive Scattering Proton Therapy (PSPT)</title>
            <description>All patients on this trial will receive concurrent weekly carboplatin and paclitaxel chemotherapy with radiation therapy 74 or 66 Gy(RBE).</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence and Time to Development of Local Failure (LF)</title>
          <description>The Primary Objective is assess and compare the incidence and time to development of local failure, among IMRT-Group 1 or PSPT-Group 2 using Bayesian randomization. Local failure was defined as treatment failure within the planning target volume plus a # 1-cm margin. Images used to report Local failure were registered with radiation dose distribution to accurately assess the location of the failure. Biopsy to confirm Local failure was strongly recommended (Data Supplement). An internal outcomes review committee reviewed each event to ensure objectivity and consistency in reporting Local failure. Final RP outcomes also were reviewed and approved by independent external experts.
Tumor recurrence after achieving complete response,
Residual tumor enlargement of 20% or more on CT according to RECIST criteria,
Recurrence of PET FDG Avidity after achieving complete metabolic response,
Increase in FDG avidity in residual tumor,
Pathologically proven recurrence</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local Failure at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From date of protocol registration until the date of documented development of adverse events (AEs) in both treatment groups, assessed up to 6 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intensity-modulated (Photon) Radiotherapy (IMRT)</title>
          <description>All patients on this trial will receive concurrent weekly carboplatin and paclitaxel chemotherapy with radiation therapy 74 or 66 Gy(RBE).</description>
        </group>
        <group group_id="E2">
          <title>Passive Scattering Proton Therapy (PSPT)</title>
          <description>All patients on this trial will receive concurrent weekly carboplatin and paclitaxel chemotherapy with radiation therapy 74 or 66 Gy(RBE).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Ischemia / Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Esophatitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="92"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Gastro Stricutre</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="92"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/ upper respiratory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Radiation Induced Dermatitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="91" subjects_affected="67" subjects_at_risk="92"/>
                <counts group_id="E2" events="65" subjects_affected="49" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Esophatitis</sub_title>
                <counts group_id="E1" events="64" subjects_affected="48" subjects_at_risk="92"/>
                <counts group_id="E2" events="45" subjects_affected="37" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="35" subjects_at_risk="92"/>
                <counts group_id="E2" events="38" subjects_affected="29" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Gastro Stricutre</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="30" subjects_at_risk="92"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="28" subjects_at_risk="92"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="56" subjects_affected="45" subjects_at_risk="92"/>
                <counts group_id="E2" events="32" subjects_affected="28" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="51" subjects_affected="41" subjects_at_risk="92"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="92"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="92"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Radiation Induced Dermatitis</sub_title>
                <counts group_id="E1" events="81" subjects_affected="65" subjects_at_risk="92"/>
                <counts group_id="E2" events="57" subjects_affected="45" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Zhongxing Liao, MD/Professor, Radiation Oncology Department</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 563-2300</phone>
      <email>zliao@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

